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In recent years, our knowledge about immunoregulation and autoimmunity has signiﬁcantly advanced, but nontoxic and more
eﬀectivetreatmentsfordiﬀerentinﬂammatoryandautoimmunediseasesarestilllacking.Oraltoleranceisofuniqueimmunologic
importance because it is a continuous natural immunologic event driven by exogenous antigen and is an attractive approach
for treatment of these conditions. Parenteral administration of anti-CD3 monoclonal antibody is an approved therapy for
transplantation in humans and is eﬀective in autoimmune diabetes. Orally administered anti-CD3 monoclonal antibody is
biologically active in the gut and suppresses experimental models of autoimmune diseases. Orally delivered antibody does not
have side eﬀects including cytokine release syndromes, thus oral anti-CD3 antibody is clinically applicable for chronic therapy.
Here we review ﬁndings that identify a novel and powerful immunologic approach that is widely applicable for the treatment of
human autoimmune conditions.
1.Introduction
Understanding how the immune system balances between
tolerance and protective immunity is still a key challenge in
immunology.Althoughseveralapproacheshavebeenusedto
treat autoimmune diseases, they usually involve nonspeciﬁc
immunosuppression, which frequently comes along with
several undesirable side eﬀects. Thus, one of the major goals
for the immunotherapy of these pathologies is the induction
of regulatory T cells that mediate immunologic tolerance. In
this scenario, the gut environment is particularly important,
as tolerance induction is the default immune pathway at
this site in physiological conditions [1]. The immunological
tolerance to antigens that gain access to the body via the
oral route has been termed “oral tolerance” [2] and it has
been classically deﬁned as the speciﬁc suppression of cellular
and/or humoral immune responses to an antigen that was
ﬁrst administered by the oral route [1, 3, 4].
Studies of oral tolerance have classically involved the
administrationoforalantigenfollowedbychallengewiththe
homologous antigen (usually in an adjuvant) to demonstrate
antigen-speciﬁc tolerance. In this context, an experimental
system that has been frequently used for the study of T-
cell function in oral tolerance is the use of TCR transgenic
(Tg) mice in which all T cells have a common TCR. Using
TCR Tg mice, we administered the cognate antigens myelin
basic protein (MBP) and ovalbumin (OVA) and investigated
how oral administration of an antigen-aﬀected speciﬁc T-
cell subsets. In these studies, we demonstrated the dose-
dependent induction of Tregs in MBP TCR Tg mice [5]a n d
deletion following high-dose oral administration of OVA in
OVA TCR Tg mice [6].
During the course of our experiments, we found that
feeding OVA to OVA TCR Tg mice induced CD4+CD25+
Treg cells [7, 8]. Other investigators also showed that oral
antigen induced CD4+CD25+ Tregs [9]. The CD4+ cells
from OVA TCR Tg fed animals had greater suppressive
properties in vitro than natural Tregs, mediated suppression
in part by both TGF-β and IL-10, and presented increased
expression of CTLA-4, a molecule known to be involved in
Treg activity [6, 10]. Although, these ﬁndings demonstrated
that oral antigen could induce/expand Tregs, administration
of OVA to OVA TCR Tg mice is dependent on TCR Tg mice
and not translatable to humans. We thus asked whether it
was possible to trigger the TCR in the gut CD4+ T cells
of wild-type mice and induce Tregs without using cognate
antigen. This possibility will be discussed in more detail
below.2 Clinical and Developmental Immunology
2. ImmuneTolerance and Anti-CD3
AntibodyTreatment
Diﬀerent mechanisms have been implicated in the induction
and maintenance of immune tolerance including deletion,
anergy,andactivecellularregulation[11].Oneapproachthat
has been successfully used for the induction/restoration of
immunetoleranceistheadministrationofCD3-speciﬁcanti-
body. Diﬀerent groups have demonstrated that parenteral
administration of anti-CD3 is eﬀective not only in animal
models of autoimmunity, including autoimmune diabetes
[12–14] and experimental autoimmune encephalomyelitis
(EAE) [15, 16]b u ta l s oi nh u m a nt r i a l so fa u t o i m m u n e
diabetes [17–19] and psoriatic arthritis [20]. Furthermore,
intravenous administration of anti-CD3 is an approved
therapy for acute transplant rejection in humans although
side eﬀects related to cytokines release limit its chronic
use [21, 22]. Humanized antibodies have been designed
to reduce these side eﬀects [23, 24] but the successful
translation might require new therapies that would be more
physiologic and less toxic and mucosal tolerance can be
exploited in this direction.
2.1. Oral Anti-CD3. It is known that anti-CD3 binds to the
ε chain of the TCR complex and when given intravenously
deletes T cells and, as mentioned above, has been shown
to be an eﬀective treatment for type 1 diabetes in the non-
obese diabetic (NOD) mouse [25]. We hypothesized that
oraladministrationofanti-CD3monoclonalantibodywould
replace the use of a cognate antigen to trigger the TCR
and would thus induce Tregs when given orally. Monoclonal
antibodies have not been given orally on the assumption
that they would be degraded in the gut and thus would
not be biologically active. Nonetheless, it is known that
orally administered cytokines [26] and peptides [27, 28]a r e
biologically active, demonstrating that orally administered
proteins are not completely degraded in the gut.
Thus, to test this hypothesis, we administered hamster
anti-mouse CD3 (2C11 clone) to SJL mice and immunized
with PLP/CFA to induce EAE. We found that oral anti-
CD3 suppressed both clinical and pathologic features of EAE
both in the PLP and MOG EAE model [29]. There was a
dose eﬀect observed, with EAE suppression by oral anti-CD3
seen at lower (5μg), but not higher doses (50μg, 500μg).
These ﬁndings were consistent with the classic paradigm of
oral tolerance in which induction of Tregs is seen at lower
but not higher doses [1]. Furthermore, it demonstrates that
induction of Tregs by oral anti-CD3 is not simply related
to administering large amounts of antibody to overcome
degradation of the antibody in the gut. Indeed, biologically
active anti-CD3 could be isolated from intestinal eluates of
animals that were given anti-CD3 orally [30]a n dw ec o u l d
also visualize anti-CD3 being taken up by gut epithelial cells
and binding to gut DCs in intestinal loop experiments [1].
The extent to which these DCs that take up anti-CD3 play a
role in the mechanism of action of oral anti-CD3 has still to
be better studied. Of note, the Fc portion of anti-CD3 was
not required, as anti-CD3 Fab 2 fragment is active orally and
induces Tregs.
2.2. Diﬀerences between Intravenous and Oral Anti-CD3
Antibody. It is known that intravenous anti-CD3 enters the
bloodstream,modulatesCD3fromthecellsurface,andleads
to the depletion of CD3+ T cells. Oral anti-CD3, on the
other hand, does not enter the blood stream or modulate
CD3 from the cell surface but acts locally in the gut to
induce Th3 type CD4+CD25−LAP+ Tregs in the MLNs.
As oral anti-CD3 does not enter the bloodstream, there is
no cytokine release syndrome, one of the main problems
with the intravenous administration of anti-CD3. In the
EAE model, intravenous anti-CD3 is eﬀective when given
after disease manifests but not when given prior to disease
induction. Oral anti-CD3, on the other hand, ameliorates
EAE both when given prior to EAE induction and at the
height of disease [29]. The explanation for this diﬀerence is
related to the fact that intravenous anti-CD3 acts primarily
by lysing disease eﬀector cells (present only after disease
induction), whereas oral anti-CD3 acts by inducing Tregs.
Intravenous anti-CD3 has been reported to induce Tregs
that act in a TGF-β-dependent fashion, but only after lysis
of T cells [12]. Therefore, immunoregulation by oral anti-
CD3 involves diﬀerent mechanisms other than intravenous
anti-CD3 and has the advantage of being safer as it is not
associated with systemic side eﬀects [31].
We found that oral anti-CD3 ameliorates disease in
other autoimmune and inﬂammatory diseases including
streptozocin-induced [30] and NOD autoimmune diabetes
(unpublished data), type 2 diabetes in the Ob/Ob mouse
[32], lupus prone SNF1mice [33], and collagen-induced
arthritis [34]. A diﬀerent group of investigators reported
that oral anti-CD3 suppresses atherosclerosis in ApoE−/−
mice [35]. In all these models, disease amelioration was
related to the induction of TGF-β-dependent Tregs that
express LAP on their surface. Indeed, in vivo treatment
of animals with anti-LAP antibody [36], abrogated tol-
erance induction by oral anti-CD3 in the EAE model
( d aC u n h ae ta l .[ 1], unpublished). We also found that nasal
anti-CD3 ameliorates lupus but does so by inducing an IL-
10-dependent CD4+CD25−LAP+ Treg as opposed to the
TGF-β-dependent LAP+ Treg induced by oral anti-CD3
[37]. This is consistent with the observation that GALT
DCs induce TGF-β-dependent Tregs versus IL-10-dependent
Tregs induced in the bronchial associated lymphoid tissue
[38]. Furthermore, these results demonstrate that mucosally
administered anti-CD3 appears to act in a fashion analogous
to mucosally administered cognate antigen [38].
The eﬀects of oral anti-CD3 raise the question whether
it is more advantageous to induce antigen-speciﬁc versus
antigen nonspeciﬁc Tregs for the treatment of autoimmune
and inﬂammatory diseases. It is assumed that the induction
of antigen-speciﬁc Tregs is preferable, as one would have
speciﬁc immune modulation with less potential side eﬀects.
Furthermore, because of the phenomenon of bystander
suppression, which we ﬁrst described in association with
oral tolerance [39], cytokines such as TGF-β released from
antigen-speciﬁc Tregs at the target organ would suppress
reactivity to other autoantigens that developed in the course
of epitope spreading. Of note, there may be target organ
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with oral anti-CD3 as we observed increased numbers of
Th3 type LAP+ Tregs in the pancreatic lymph nodes of
autoimmune diabetic mice [30], and this has been suggested
for atherosclerosis models [29]. Furthermore, in conditions
such as type 2 diabetes, lupus, and atherosclerosis, there
are not well-deﬁned target antigens and in these conditions
induction of antigen nonspeciﬁc Tregs by anti-CD3 may be
preferable. Studies are in progress to test the combination of
mucosal anti-CD3 given with antigen. As discussed below,
oral anti-CD3 is currently being tested in humans.
3.Oral Anti-CD3inHumans
Oral anti-CD3 has been tested in a phase 1 study in healthy
human volunteers (3 per group) who were orally adminis-
tered 0.2, 1.0, or 5.0mg of mouse anti-human OKT3 mAb
daily for 5 days [31]. Immunologic eﬀects were observed in
the peripheral blood and consisted of transient proliferation,
suppression of Th1/Th17 responses, increased expression
of Treg markers, increased TGF-β/IL-10, and decreased
IL-23/IL-6 expression in dendritic cells. No side eﬀects
were observed. There were no human anti-mouse antibody
responses, changes in CD3 cells in the blood, or modulation
of CD3 from the surface of T cells. The optimal dose was
found to be 1mg.
Oral OKT3 mAb has also been recently tested in a
single-blind randomized placebo-controlled phase 2a study
in patients with nonalcoholic steatohepatitis (NASH) and
altered glucose metabolism that included subjects with type-
2 diabetes [40]. The study was performed at the Hadassah-
Hebrew University Medical Center in Jerusalem, Israel.
OKT3 or placebo was orally administered (9 per group) at
doses of 0.2, 1.0, and 5.0mg. In the NASH study 36 subjects
were treated once daily for 30 days with ﬁnal follow-up 60
days after the ﬁrst dose.
Oral OKT3 was safe with no adverse eﬀects or sys-
temic toxicity as measured by blood hematology, chemistry,
immunological safety markers, and physical signs. There
were no changes in blood levels of CD3, CD4, or CD8-
positive cells. Oral OKT3 induced regulatory T cells, which
generally persisted to day 60 and trends in cytokine pro-
duction consistent with eﬀects observed in the phase 1
clinicalstudyandinanimalmodels.Positivetrendsinclinical
parameters, some of which were statistically signiﬁcant were
also observed including a reduction in liver enzymes and
reduced blood levels of glucose and insulin. Several of the
positiveeﬃcacytrendspersistedtoday60followingcessation
of treatment at day 30. Some subjects had increased levels
of serum antibodies directed against OKT3, which did not
aﬀect the positive trial results observed. These results suggest
thatoralanti-CD3mAbmayhaveclinicalbeneﬁtforsubjects
withNASHortype-2diabetes.Conﬁrmatorystudiesarenow
needed, including studies with humanized antibodies. These
results will provide the basis for investigating oral/nasal anti-
CD3 in other autoimmune and inﬂammatory conditions in
humans.
Recently, an important development that will facilitate
studies related to the use of humanized anti-CD3 antibodies
was the generation of transgenic mice expressing the ε
chain of the human CD3 complex on the NOD background
(NOD-huCD3ε). These mice develop spontaneous diabetes
to the same extent as the wild-type NOD mice and when
treated with a humanized anti-CD3 antibody, they exhibited
a complete and durable disease remission [41]. This model
will be very useful for studies evaluating anti-human CD3
antibodies, including its administration by oral route, and
this will open new perspectives and clarify their potential
clinical utility.
4. Summary
Mucosal tolerance is an attractive approach for the treatment
of autoimmune inﬂammatory diseases as it is a clinically
applicable physiologic manner to suppress inﬂammation
throughtheinductionofregulatoryTcells.Itslackoftoxicity
and ease of administration are also important features
desired for an eﬀective immunotherapy. Several studies
have demonstrated that oral (or nasal) administration of
anti-CD3 monoclonal antibodies can be used to induce
immune tolerance and is eﬀective in the treatment of
animal models of autoimmune diseases. These studies have
also demonstrated that mucosal administration of anti-CD3
antibodies does not lead to detectable side eﬀects including
cytokine release syndrome or antiglobulin response and thus
could be used as a continuous therapy for the treatment of
theseconditions.Insummary,resultspresentedhereindicate
that oral administration of anti-CD3 antibodies represents
a new avenue that can be investigated for the treatment of
autoimmune diseases.
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